| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.4K | 7.3% |
| Total Income | 1.4K | 7.3% |
| Expenditure | 1.4K | 8.9% |
| PBT | 29.94 | 1871.6% |
| Net Profit | 48.92 | 304.0% |
| OPM | 0.28% | 1.72pp |
| NPM | 3.44% | 2.65pp |
| EPS | 2.95 |
agilon health Reports Q1 2026 Results, Raises Full-Year Guidance
07 May 2026 · 7 May, 1:44 am
Summary
agilon health reported its first quarter 2026 results, with total revenue of $1.42 billion, a 7% decrease compared to the prior year. However, gross profit increased to $65 million, and net income rose significantly to $49 million. The company's medical margin was $149 million, and adjusted EBITDA reached $54 million. Due to the strong first-quarter performance, agilon health increased its full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA.
Key Highlights
- 1
Agilon health's total revenue for the first quarter of 2026 was $1.42 billion, a decrease of 7% compared to $1.53 billion in the first quarter of 2025.
- 2
The company's gross profit increased to $65 million in the first quarter of 2026, compared to $51 million in the first quarter of 2025.
- 3
Net income for the first quarter of 2026 was $49 million, a significant increase from $12 million in the first quarter of 2025.
- 4
Medical margin for the first quarter of 2026 was $149 million, compared to $128 million in the first quarter of 2025.
- 5
Adjusted EBITDA for the first quarter of 2026 was $54 million, a substantial increase from $21 million in the first quarter of 2025.
- 6
The company increased its full-year 2026 guidance for total revenues to a range of $5.68 billion to $5.805 billion.
- 7
Full-year 2026 medical margin guidance was raised to a range of $350 million to $400 million.
Management Comments
Ronald A. Williams
Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We are seeing early returns from investments in data and technology, clinical execution, and operating discipline. We are also strengthening our Total Care Model—expanding clinical pathways, improving quality, and deepening payor alignment—positioning us for more predictable outcomes and sustained margin expansion. We remain confident in our 2026 outlook and long-term growth trajectory. We are also excited to welcome Tim O’Rourke as CEO, who brings more than 25 years of healthcare leadership. Under Tim’s leadership we expect to further sharpen our focus on execution with faster pull through from action to outcome and deliver increased value for all stakeholders.”
Informational and educational content only. Not investment advice.